Phenotypic Consequences of

ABCB1 drug resistance high-grade serous ovarian cancer high-throughput drug screening

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
11 Nov 2021
Historique:
received: 28 09 2021
revised: 05 11 2021
accepted: 05 11 2021
entrez: 27 11 2021
pubmed: 28 11 2021
medline: 28 11 2021
Statut: epublish

Résumé

Despite high response rates to initial chemotherapy, the majority of women diagnosed with High-Grade Serous Ovarian Cancer (HGSOC) ultimately develop drug resistance within 1-2 years of treatment. We previously identified the most common mechanism of acquired resistance in HGSOC to date, transcriptional fusions involving the ATP-binding cassette (ABC) transporter

Identifiants

pubmed: 34830797
pii: cancers13225644
doi: 10.3390/cancers13225644
pmc: PMC8616176
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : National Health and Medical Research Council
ID : APP1124309
Organisme : Victorian Cancer Agency
ID : ECSG15012
Organisme : US National Cancer Institute U54
ID : U54CA209978
Organisme : NHMRC CJ Martin Overseas Biomedical Fellowship
ID : APP1111032
Organisme : Therapeutic Innovation Australia Pipeline Accelerator Grant
Organisme : Cancer Systems Biology Center U54 grant
ID : U54CA209978
Organisme : Cancer Council Victoria
ID : APP1184894
Organisme : NHMRC
ID : APP1161198

Références

Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
Sci Rep. 2015 Jun 12;5:11432
pubmed: 26066708
Cell Res. 2007 Apr;17(4):311-23
pubmed: 17404598
Int J Mol Sci. 2020 May 02;21(9):
pubmed: 32370233
PLoS One. 2015 Jan 30;10(1):e0116747
pubmed: 25635866
Int J Cancer. 2002 Jun 1;99(4):520-8
pubmed: 11992541
Cancer Immun. 2004 Jan 23;4:1
pubmed: 14738373
Biochem Biophys Res Commun. 2008 Aug 1;372(3):440-6
pubmed: 18485890
Sci Data. 2017 Nov 07;4:170166
pubmed: 29112189
Pharmacogenet Genomics. 2011 Mar;21(3):152-61
pubmed: 20216335
Cancers (Basel). 2021 Jan 29;13(3):
pubmed: 33572972
Cancer Res. 2005 Aug 1;65(15):6660-7
pubmed: 16061646
Mol Cell Proteomics. 2012 Apr;11(4):M111.014647
pubmed: 22159717
Pharmacol Rev. 1990 Sep;42(3):155-99
pubmed: 2217530
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Cell. 2000 Nov 22;103(5):757-68
pubmed: 11114332
Med Mol Morphol. 2005 Mar;38(1):2-12
pubmed: 16158173
Nat Rev Drug Discov. 2006 Mar;5(3):219-34
pubmed: 16518375
J Biochem. 2008 Apr;143(4):517-24
pubmed: 18174186
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Genes Chromosomes Cancer. 1998 Sep;23(1):44-54
pubmed: 9713996
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Biol Open. 2017 Jun 15;6(6):723-731
pubmed: 28483980
Lancet. 2021 Jan 23;397(10271):254-256
pubmed: 33485431
Cancer Biol Ther. 2006 Mar;5(3):300-4
pubmed: 16410724
Nature. 2015 May 28;521(7553):489-94
pubmed: 26017449
J Mol Biol. 1999 Oct 22;293(2):381-99
pubmed: 10529352
Cell. 1986 Nov 7;47(3):381-9
pubmed: 2876781
Cell Death Dis. 2011 Jul 07;2:e179
pubmed: 21734725
J Pathol. 2010 May;221(1):49-56
pubmed: 20229506
Cold Spring Harb Perspect Med. 2018 Mar 1;8(3):
pubmed: 28710258
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Crit Rev Oncol Hematol. 2015 Nov;96(2):220-56
pubmed: 26100653
Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4028-33
pubmed: 9108099
J Biol Chem. 1993 Sep 15;268(26):19505-11
pubmed: 8103518
PLoS One. 2016 Nov 3;11(11):e0166058
pubmed: 27812204
J Biol Chem. 2000 Jan 28;275(4):2979-85
pubmed: 10644769
Reprod Biol Endocrinol. 2004 Jan 07;2:4
pubmed: 14711375
Nat Rev Clin Oncol. 2020 Nov;17(11):675-686
pubmed: 32699310
Nat Commun. 2019 Mar 20;10(1):1295
pubmed: 30894541
Nat Protoc. 2012 Apr 05;7(5):839-49
pubmed: 22481527
Cancer Res. 2003 Mar 1;63(5):895-901
pubmed: 12615699
Gynecol Oncol. 2013 Oct;131(1):8-14
pubmed: 23917080
Mol Biol Cell. 2009 Aug;20(15):3598-607
pubmed: 19515834
Biochim Biophys Acta. 1976 Nov 11;455(1):152-62
pubmed: 990323
Biomed Pharmacother. 2020 Nov;131:110718
pubmed: 32932043
Obstet Gynecol. 2017 Mar;129(3):439-447
pubmed: 28178043
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Arch Toxicol. 2021 Jul;95(7):2279-2297
pubmed: 34003341
Endocr Relat Cancer. 2018 May;25(5):R303-R318
pubmed: 29487129
Nat Rev Cancer. 2015 Aug;15(8):473-83
pubmed: 26156638
Cold Spring Harb Perspect Biol. 2012 Jan 01;4(1):a004903
pubmed: 21937732
Lancet Oncol. 2014 Jul;15(8):852-61
pubmed: 24882434
Nat Rev Cancer. 2018 Jul;18(7):452-464
pubmed: 29643473
J Biol Chem. 2015 Dec 4;290(49):29652-62
pubmed: 26468294
Nat Rev Cancer. 2010 Feb;10(2):147-56
pubmed: 20075923
Int J Cancer. 2015 Feb 15;136(4):E188-96
pubmed: 25156304
Int J Breast Cancer. 2011;2011:967419
pubmed: 22332018

Auteurs

Kathleen I Pishas (KI)

Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC 3010, Australia.

Karla J Cowley (KJ)

Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.

Ahwan Pandey (A)

Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.

Therese Hoang (T)

Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.

Jessica A Beach (JA)

Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.

Jennii Luu (J)

Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.

Robert Vary (R)

Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.

Lorey K Smith (LK)

Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC 3010, Australia.

Carolyn E Shembrey (CE)

Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Department of Clinical Pathology, Faculty of Medicine, Dentistry, and Health Science, The University of Melbourne, Melbourne, VIC 3000, Australia.

Nineveh Rashoo (N)

Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.

Madelynne O White (MO)

Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.

Kaylene J Simpson (KJ)

The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC 3010, Australia.
Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.

Andrea Bild (A)

Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA.

Jason I Griffiths (JI)

Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA.

Dane Cheasley (D)

Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC 3010, Australia.

Ian Campbell (I)

Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC 3010, Australia.

David D L Bowtell (DDL)

Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC 3010, Australia.

Elizabeth L Christie (EL)

Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC 3010, Australia.

Classifications MeSH